European Medicines Agency (EMA) Blogs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
Using Novel Digital Twins of Clinical Trial Participants, Unlearn is Accelerating Clinical Research to Help Bring New Treatments to Patients Sooner Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, today announced a $50M Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company’s mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering ca...
Source: EMR and HIPAA - February 29, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT 8VC Altimeter Capital Charles Fisher DCVC DCVC Bio Epic Ventures Health IT Funding Health IT Fundings Health IT Investment Insight Partners Mubadala Capital Necessary Venture Capital Pauline Yang Source Type: blogs

Lowering Drug Costs and Prices by Expanding Access to Biosimilars
Jeffrey A. SingerToday Senator Mike Lee (R ‑UT) introduced theBiosimilar Red Tape Elimination Act. Thebill seeks to reduce health care costs by streamlining the Food and Drug Administration ’s process to approve biosimilar drug products. It does this by prohibiting the FDA from requiring biosimilar drugs to undergo “switching studies” before the agency approves them as interchangeable with the original biological medicine.Unlike conventional medicines, which drug companies chemically synthesize to a specific molecular structure, biological medicines have natural sources, are complex, and may contain combinatio...
Source: Cato-at-liberty - November 18, 2022 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs

COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
Financing will be used to accelerate and further diversify COTA’s oncology real-world data products and services COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management, a healthcare investment firm. Deerfield invests across the life science, medical device, diagnostic, digital health, and health service industries at every stage of evolution. In conjunction, COTA announced it has raised additional capital from existing investors. The company will use this new funding to further expand its real-world data platform and services...
Source: EMR and HIPAA - November 1, 2022 Category: Information Technology Authors: Healthcare IT News Tags: Genomics-Precision Medicine Health IT Company Healthcare IT Baptist Health South Florida Bristol-Myers Squibb Clinicogenomics COTA COTA Inc. data analytics Deerfield Deerfield Management EMA European Medicines Agency FDA Food a Source Type: blogs

Vaccine Myocarditis Update
BY ANISH KOKA The European Medicines Agency decided on July 19, 2021 that myocarditis and pericarditis be added to the list of adverse effects of both messenger RNA (mRNA) based vaccines (BNT162b2 [Pfizer-BioNTech] and mrna-1273 [Moderna]) against COVID-19. This advice was based on numerous reports of myocarditis that followed a clinical pattern that strongly suggested a causal link between these particular vaccines and myocarditis/pericarditis. The adverse events that appeared to be predominantly in young men typically occurred within a week after injection, and were clustered after the second dose of the vaccine serie...
Source: The Health Care Blog - September 7, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: COVID-19 Health Policy Uncategorized Anish Koka cardiology Source Type: blogs

Novartis' Sandoz Is Back In The Insulin Biosims Market. Can It Succeed?
Back in December 2018, the Sandoz division of Swiss pharmaceutical giant Novartis announced (see the full announcementHERE) " Sandoz enters into commercialization and supply agreement for insulin biosimilars " . It also revealed that Sandoz had entered a " commercialization and supply agreement with Gan& Lee " which it added was " a leading insulin supplier headquartered in China with more than 20 years ' experience in insulins and production capacity with attractive cost of goods sold (COGS) structures " .Few Americans have ever heard of Gan& Lee, although this year, at the American Diabetes Association ' s 82nd S...
Source: Scott's Web Log - July 22, 2022 Category: Endocrinology Tags: insulin analogs 2022 Biosimilar biosimilars generics insulin analogues Novartis Sandoz Source Type: blogs

Fight Aging! Newsletter, November 1st 2021
In conclusion, mitophagy pathways play an important role in maintaining physiological homeostasis, are involved in the mechanisms of aging and neurodegenerative disorders, and represent promising targets for the development of potential therapeutic agents aimed at regulating mitochondria quality control in neurons and glial cells. A significant number of molecules that induce or inhibit mitophagy are currently under consideration, which may be useful for testing hypotheses or developing drugs for the treatment of neurodegenerative diseases. The validation of promising drugs in animal and cell models, including neurons and ...
Source: Fight Aging! - October 31, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Journalistic Balance Run Amok in the Matter of Aging
The implementation of journalistic balance is a self-parodying genre of writing. In the case in which the scientific community is working towards saving countless lives, by implementing therapies targeting the underlying mechanisms of aging, the paint-by-numbers journalist and editor duo will dutifully find a curmudgeonly figure who thinks that everyone should just get on and die, and put in a few quotes in order to balance the article. The piece here is an example of exactly this phenomenon; it is left as an exercise for the reader to identify the other popular media checkboxes lazily checked in the course of its few page...
Source: Fight Aging! - October 27, 2021 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

I Am Sure The Technology Investments In Many States Are Paying Off In This Search!
This appeared last week: NSW hospitals hunt for rare blood clots linked to AstraZeneca vaccine By Kate Aubusson April 8, 2021 — 5.00am NSW emergency departments are scouring medical records for blood clot cases linked to the AstraZeneca COVID-19 vaccine as international medicines regulators inch closer to declaring the vaccine may cause the extremely rare condition. The state’s vaccinators are warning anyone receiving the AstraZeneca shot to be on alert for blood clot symptoms as a precaution following the case of a 44-year-old man hospitalised with a severe and extremely rare clotting disorder in Melbourne on Friday. ...
Source: Australian Health Information Technology - April 16, 2021 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Blocking J & J and AstraZeneca Vaccines Shows the FDA Has Not Changed Its Stripes
Michael F. CannonThe U.S. Food and Drug Administration is recommending the federal government and state governments stop administering Johnson& Johnson’s Covid‐19 vaccine. Some 7 million Americans have received the vaccine, whose regimen requires only one dose. The FDA issued the recommendation afterreports that six women between the ages of 18 and 48 developed blood clots after taking the vaccine. One of the women is in a hospital in critical condition. Another died. While the FDA’s recommendation is merely advisory, it is likely to halt vaccinations at federal facilities. Statesincluding Ohio, New York, andC...
Source: Cato-at-liberty - April 13, 2021 Category: American Health Authors: Michael F. Cannon Source Type: blogs

Anti-Radiation Poison Pill Also Effective at Eliminating GBCAs from the Body
The chelator pill, a medication that was developed to rid the body of radioactive elements, has a 96 percent efficacy rate at preventinggadolinium from depositing in bodies of patients who have just undergone MRI, according to researchers from theU.S. Department of Energy ' s Lawrence Berkeley National Laboratory. Gadolinium-based contrast agents (GBCA) are used in around a third of all MRI procedures. They ’ve been a controversial topic in recent years, and traces of the agent can remain in the brain for years after screenings. The Food and Drug Administration (FDA) has requiredhealthcare providers to issue a GBCA Med...
Source: radRounds - September 22, 2019 Category: Radiology Authors: Julie Morse Source Type: blogs

Has Opioid Hysteria Risen to the Point Where Innovation Is Forbidden?
On November 2 the Food and Drug Administration announced the approval of Dsuvia, a sublingual tablet containing the powerful fentanyl analog, sufentanil. Sufentanil has been used for years in the hospital setting, primarily in intravenous form for anesthesia. It is roughly 5 to 10 times more potent than fentanyl, and thus has a significant overdose potential. The FDA reached this decision following a 10-3 vote in favor of the drug’s approval by the Anesthetic and Analgesia Drug Products Advisory Committee (AADPAC),based on data from multicenter trials. It was not approved for outpatient use, but for use only in ...
Source: Cato-at-liberty - November 6, 2018 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs

FDA Transparency Blueprint Issued
Most everyone even tangentially related to the pharmaceutical industry knows and understands that right now, transparency is a hot topic. In Winter 2017, The Journal of Law, Medicine & Ethics published a Special Supplement to Volume 45:4, a written companion to a January 16, 2018 symposium entitled, “Blueprint for Transparency at the U.S. Food and Drug Administration.” According to the Letter from the Editor included in the Special Supplement, “guest editors Anna L. Davis, James Dabney Miller, Joshua M. Sharfstein, and Aaron S. Kesselheim and their co-authors have tackled the challenging topic of transparency at...
Source: Policy and Medicine - March 28, 2018 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

Interview with Devyn Smith PhD, COO of Sigilon Therapeutics
Sigilon Therapeutics is a Cambridge, MA-based biotech company developing innovative therapeutics by encapsulating cells in a novel coating that renders them invisible to the immune system. The engineered cells contained in the company’s particles can provide long-term continuous therapy for a range of chronic disorders, including hemophilia and diabetes, and eliminate the need for intermittent injection or infusion. With this technological breakthrough Sigilon hopes to “fundamentally change the trajectory of disease treatment.” Medgadget editor Tom Peach recently spoke with Devyn Smith PhD, Chief Strategy Officer of ...
Source: Medgadget - March 13, 2018 Category: Medical Devices Authors: Tom Peach Tags: Exclusive Genetics Materials Medicine Pediatrics Source Type: blogs

Two gadolinium-based contrast agents are banned in Italy
Wellwellwellwellwell! WELL! I just read a bit of welcome (or, wellcome!) news in Italian. If you understand Italian, here’s the link: goo.gl/JYN8ec. In a nutshell, beginning today, yes, TODAY!, two contrast agents used in MRIs have been banned in ITALY. And, quelle surprise (not), they are gadolinium-based. Remember the study that came out some years ago about how much myeloma cells simply LOVED gadolinium, and proliferated at mad rates when placed in it? If not, just do a search of my blog for “gadolinium.” Gadolinium can also have a bunch of not-very-nice side effects… The reason for this ban isn...
Source: Margaret's Corner - February 28, 2018 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll gadolinium MRI myeloma Source Type: blogs

Fight Aging! Newsletter, December 4th 2017
In this study, we integrated atomic force microscopy (AFM) and molecular approaches to determine whether increased stiffness of aortic VSMCs in hypertensive rats is ROCK-dependent, and whether the anti-hypertensive effect of ROCK inhibitors contributes to the reduction of aortic stiffness via changing VSMC mechanical properties. Despite a widely held belief that aortic stiffening is associated with changes in extracellular matrix proteins and endothelial dysfunction, our recent studies demonstrated that intrinsic stiffening of aortic VSMCs, independent of VSMC proliferation and migration, is an important contributo...
Source: Fight Aging! - December 3, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs